Market Response Mixed as HeartBeam Shares Dip Despite Positive Trial News Despite reporting strong clinical trial results, HeartBeam shares closed at $1.81, down over 7% for the day. Analyst sentiment remains cautiously optimistic, with price targets averaging $5.00. The company faces ongoing financial challenges but continues to attract investor interest, particularly from international markets.56